ORLANDO, FLORIDA — Given the intersection between rheumatology and dermatology for many patients with autoimmune diseases, it’s helpful to hear from specialists in both fields regarding disease management strategies.
![](https://www.the-rheumatologist.org/wp-content/uploads/2023/06/GenericPsoriasis_AdobeStock_500x270-150x150.jpg)
ORLANDO, FLORIDA — Given the intersection between rheumatology and dermatology for many patients with autoimmune diseases, it’s helpful to hear from specialists in both fields regarding disease management strategies.
After examining study data from pediatric patients with both psoriasis and psoriatic arthritis (PsA), the FDA approved ustekinumab as a treatment for patients aged 6–17 years old with PsA.
Recent research reinforces the finding that psoriasis patients have a slightly increased risk of cancer, specifically keratinocyte cancer and lymphomas. However, the study found no association between cancer and the use of biologic treatments in this patient population…
In a head-to-head study, ixekizumab was a more effective treatment for nail psoriasis than ustekinumab and resulted in greater skin clearance for patients with plaque psoriasis…
Research has shown ixekizumab improves pain and the sexual health of patients with genital psoriasis…
Reuters Staff |
NEW YORK (Reuters Health)—The ongoing novel coronavirus pandemic has raised concerns about whether biologic therapy could make psoriasis patients more susceptible to SARS-CoV-2, the virus behind COVID-19. Mark Lebwohl, MD, from Icahn School of Medicine at Mount Sinai Hospital in New York and colleagues address this issue in a letter in the Journal of the…
New research shows tildrakizumab may significantly improve psoriasis in patients with active psoriatic arthritis…
The Scottish Medicines Consortium has released a detailed advice document recommending risankizumab for treating adults with psoriasis…
Japan has approved risankizumab for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults…
David Douglas |
NEW YORK (Reuters Health)—In patients with psoriasis and psoriatic arthritis, the incidence of atrial fibrillation and major adverse cardiovascular events does not differ between treatment with ustekinumab and TNF inhibitors, according to a large observational study. “Given a high cardiovascular risk among patients with psoriasis and psoriatic arthritis,” Seoyoung C. Kim, MD, ScD, MSCE, told…